Thomas Pabst

108PUBLICATIONS
307CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Solid tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (108)

|Sep 30, 2026
Immunotherapy refractoriness and early post-alloHCT relapse define ultra-high-risk B-ALL after CD19 CAR T-cell therapy.

|Sep 24, 2026
Adolescents and young adults with cancer in Switzerland: a large retrospective single-centre cohort analysis of key care pathways and outcomes by sex and age.

|Aug 27, 2026
Clinical Impact of a Common PDCD1 Germline Variant in DLBCL Patients Treated with CAR-T Cell Therapy.

|Jul 15, 2026
Clinical Impact of a Germline CD19 Variant on Treatment Outcome After CAR-T Cell Therapy in Relapsed/Refractory Mantle Cell Lymphoma.

|Jul 15, 2026
Low-Frequency PPM1D Gene Mutations Affect Treatment Response to BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.

|Jun 26, 2026
Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients.

Pageof 18

Frequent Collaborators

67 joint publications

Vera Ulrike Bacher

30 joint publications

Katja Seipel

17 joint publications

Michael Daskalakis

13 joint publications

Henning Nilius